Introduction
lats is a novel tumor suppressor gene originally isolated from Drosophila by the mosaic screening approach (Xu et al., 1995) . Somatic cells mutant for Drosophila lats undergo extensive proliferation and form large tumors with morphological characteristics similar to those of human tumors. The mammalian homologues of lats were recently isolated Yabuta et al., 2000) . Introducing the human lats (LATS1) gene into Drosophila lats mutants can prevent tumor formation and support normal development in¯ies, demonstrating that the function of these genes are conserved from¯ies to humans . Moreover, mice de®cient for mouse lats (Lats1) developed soft tissue sarcomas and ovarian stromal cell tumor and exhibited high sensitivity to carcinogen . Most interestingly, LATS1 was also shown to be phosphorylated and bind CDC2 at early mitosis. The LATS1/CDC2 complex lacks Cyclin A or B and is inactive for histone H1 kinase activity .
To examine the role of LATS1 in cell cycle progression, we generated LATS 7/7 MEF cells. By utilizing adenovirus-mediated LATS1 gene transfer, we show that overexpression of LATS1 in LATS1 7/7 MEF cells inhibits CDC2 activity and causes G 2 /M arrest. Furthermore, overexpression of LATS1 in multiple human tumor cell lines causes either G 2 /M arrest or apoptosis. In vivo tumorigenecity experiments further support the in vitro results, demonstrating the growth suppression ability of the LATS1 molecule. MEF cells markedly increased cell population in G 2 /M phase ( Figure  1a ). This cell cycle arrest induced by LATS1-Ad is speci®c because no increase in G 2 /M cell population was found in LATS 7/7 MEF cells infected with recombinant b-galactosidase adenovirus (b-gal-Ad). Since CDC2 kinase is the major regulator responsible for the progression of G 2 /M transition and LATS1 was shown to bind CDC2 , we subsequently tested whether the G 2 /M arrest caused by LATS1 is due to its inhibition of CDC2 kinase activity. Consistent with our previous ®nding , CDC2 precipitated with LATS1 does not contain kinase activity (Figure 1b) . Importantly, CDC2/Cyclin B kinase activity signi®cantly decreased after LATS1-Ad infection, as detected in H1 kinase assay with proteins immunoprecipitated with antiCyclin B antibody (Figure 1b) . Downregulation of CDC2 kinase activity is not due to reduced level of CDC2 or Cyclin B, because no dierences were found in CDC2 and Cyclin B levels irrespective of whether or not LATS1 was overexpressed ( Figure  1c) . Morphologically, the cells infected with LATS1-Ad are large and mostly round, similar to that of mitotic cells (data not shown). While LATS1 overexpression aects G 2 /M transition in HeLa, C33A, and U87MG cells, it results in an increase of cell death in the rest of the tumor cells (Figure 2b ). To further con®rm that LATS1 indeed induces apoptosis in human cancer cells, we infected HCT116 cells with increasing MOI of LATS1-Ad. As shown in Figure 4a , with the increase of virus infected, the percentage of sub-G 1 cells gradually increased. This increase is well correlated with an enhancement of LATS1 level in the cells (Figure 4a,d) . The DNA fragmentation induced by LATS1 was further con®rmed in situ by terminal deoxynucleotidyltransferasemediated dUTP nick end labeling (TUNEL) staining. As shown in Figure 4b , only the cells infected with LATS1-Ad rather than Ad have fragmented nuclei incorporated with¯uorescein-labeled dUTP, indicating apoptosis-induced DNA strand breaks. Since activation of caspase-3 is one of the major steps for apoptosis induction, we also examined the caspase-3 activity after LATS1 infection. Consistent with the induction of apoptosis, caspase-3 activity was signi®-cantly higher at higher MOI of LATS1-Ad. To characterize further on the molecular mechanism of LATS1-induced apoptosis, we examined the level of apoptosis-associated proteins, p53, Bcl-2 and Bax, after infection of HCT116 cells with LATS1-Ad. With the increase of LATS1 level in the cells, p53 was progressively induced (Figure 4d ). However, no signi®cant changes were found in the levels of the other two apoptotic proteins, Bcl-2 and Bax.
Results

Overexpression of LATS1 in homozygous LATS1-deficient (LATS
Overexpression of LATS1 suppresses human tumor cell growth in vitro and in vivo To examine whether LATS1 can suppress human tumor cell growth in vitro, we examined the proliferation of these six human tumor cell lines derived from various human cancer tissues after overexpression of LATS1 in these cells. Infection of LATS1-Ad at 100 MOI into these human tumor cells dramatically inhibits their cell proliferation independent of endogenous LATS1 level (Figure 5a) . As a control, no growth inhibition was found when the tumor cells were infected with the viral vector control Ad at the same MOI (Figure 5a ). Consistently, anchorage-independent growth of tumor cells on soft agar was also signi®cantly suppressed by LATS1-Ad (Figure 5b ). To examine whether LATS1 can suppress tumor formation in vivo, we injected tumor cells infected by either Ad or LATS1-Ad into nude mice and monitored tumor progression every week for 6 weeks. As expected, all the mice injected with human tumor cells infected with the control Ad virus developed tumors 4 weeks after the injection. However, mice injected with all six lines of human tumor cells that are overexpressed with LATS1 (LATS1-Ad) developed no tumors 6 weeks after the injection, except for one small tumors in mouse injected with A549 (Table 1) .
Discussion
Among the tumor suppressor genes identi®ed so far, most suppress cell proliferation by inducing G 1 arrest. For example, the most frequently mutated genes in human cancer, such as Rb, p53, PTEN and p16INK4A, are all involved in the G 1 phase cell cycle checkpoint (Agarwal et al., 1995; Di Cristofano and Pandol®, 2000; Harbour and Dean, 2000) . In contrast, few tumor suppressors have been identi®ed to be involved in G 2 /M regulation. The G 2 /M transition is mostly controlled by a protein kinase CDC2. Activation of CDC2 kinase activity through depohosphorylation at Thr-14/Thr-15 by CDC25C has been considered to be the critical step for M phase progression (Elledge, 1996) . Recently, the p53 tumor suppressor protein was found to be implicated in the control of the G 2 /M transition. Overexpression of p53 in p53-de®cient human ®broblasts resulted in both G 1 and G 2 /M arrest (Agarwal et al., 1995) . Further studies demonstrated that p53 induced G 2 /M arrest by inhibiting the CDC2/cyclin B1 kinase activity through upregulation of 14-3-3, an inhibitor of CDC25C, or downregulation of cyclin B1 (Hermeking et al., 1997; Innocente et al., 1999) . Other tumor suppressors, such as BRCA1, RIZ1 and MXI1, have also been found to induce G 2 /M arrest in human cancer cells (Wechsler et al., 1997; He et al., 1998; MacLachlan et al., 2000) . However, the mechanisms for their growth arrest are still unclear.
In this study, we provided evidence that the human homologue of Drosophila tumor suppressor, LATS1, can negatively regulate cell growth in vitro and in vivo by causing G 2 /M arrest through inhibition of CDC2 kinase activity. Moreover, growth suppression activity of LATS1 seems independent of its endogenous level in the cells. Thus, LATS1, like p21 or p16 (El-Deiry et al., 1993; Quelle et al., 1995) , may be a general negative regulator of cell cycle progression. Similar to LATS1, GADD45, a protein whose gene is p53 downstream gene and DNA damage induced, was also found to be associated with CDC2 and inhibit the CDC2/cyclin B1 kinase activity . Overexpression of GADD45 causes G 2 /M arrest in human normal ®broblasts and colorectal carcinoma cells . Recently, 14-3-3s was also shown to cause G 2 /M arrest by inhibiting CDC2 function through binding and sequestering CDC2 in the cytoplasm (Chan et al., 1999) . Therefore, LATS1, GADD45, and 14-3-3 represent a new group of proteins that can negatively regulate cell proliferation by binding and inactivating CDC2. In addition to the function of cell cycle arrest, tumor suppressors can also suppress tumors by inducing apoptosis. Overexpression of tumor suppressors p53, PTEN, p16INK4A and BRCA1 can cause apoptosis in human cancer cell lines derived from various cancers (Levine, 1997; Di Cristofano and Pandol®, 2000; Kataoka et al., 2000) . However, the mechanisms by which each tumor suppressor gene induces apoptosis are diverse. For example, p53 induces apoptosis by inducing proapoptotic genes such as bax and p53AIP1 (Oda et al., 2000) . . In this study, we found that the level of p53 and the caspase-3 activity is signi®cantly induced under enforced expression of LATS1, indicating that LATS1 may induce apoptosis through p53 and caspase-3 pathways. On the other hand, the levels of Bax and Bcl-2 were unchanged after induction of apoptosis by LATS1, suggesting that apoptosis induced by LATS1 may not be mediated through upregulation of bax or downregulation of bcl-2. Since LATS1-induced apoptosis was observed only in cancer cell lines containing wild-type p53 (A549, HCT116 and MCF7), but not in those containing HPV E6-mediated degraded or mutated p53 (HeLa and C33A), p53 may be involved in LATS1-induced apoptosis. In addition, p53 mRNA was also induced after overexpression of LATS1 (unpublished data). Therefore, LATS1 may upregulate p53 by directly or indirectly inducing p53 transcription. Since p53 induces apoptosis by upregulating various proapoptotic genes (Levine, 1997; Oda et al., 2000) , it is still unclear which gene is directly responsible for LATS1-mediated apoptosis. Further studies will be helpful to under the signal transduction pathway of LATS1-induced apoptosis.
The lats gene was ®rst identi®ed in Drosophila as a tumor suppressor. Mice de®cient for Lats1 also develops tumors. In this study, we demonstrate that LATS1 is a potent growth suppressor in all the human tumor cell lines examined. Furthermore, like many other known human tumor suppressors, it also suppresses growth by aecting both cell cycle progression and apoptosis. These observations strongly argue that LATS1 may play a role in tumorigenesis in humans and screening potential LATS1 mutations in human cancer cells will be a warranted endeavor.
Materials and methods
Cell lines
LATS
7/7 MEF cells were derived from 13.5-day-old embryo of LATS 7/7 mice. HeLa human cervical adenocarcinoma cells, C33A human cervical squamous carcinoma cells, A549 human lung carcinoma cells, HCT116 human colorectal carcinoma cells, MCF7 human breast carcinoma cells, and U87MG human glioblastoma cells were obtained from the American Type Culture Collection. Culture conditions and methods were as described .
Viruses
To produce LATS1 adenovirus (Ad), the full-length LATS1 cDNA was ®rst cloned into the pCA14 vector. The resulting plasmids or the pCA14 vector alone were cotransfected with the adenovirus packaging plasmid pJM17 into 293 cells using LipofectAMINE (GIBCO ± BRL, Rockville, MD, USA). The transfected cells were then covered by 0.5% agarose and incubated at 378C for 10 ± 14 days. Potential plaques were subsequently isolated, eluted, ampli®ed and examined for the presence of Ad DNA or the expression of LATS1 by DNA extraction and restriction enzyme digestion or Western blot. The positive Ad or LATS1-Ad viruses were ampli®ed in 293 cells and tittered.
Cell proliferation, soft agar and tumorigenicity assays Cells were infected with Ad or LATS1-Ad at MOI of 100 for 2 h. The procedures for cell proliferation, soft agar and tumorigenicity assays were as described (Yang et al., 1996) .
Western blot
Western blot analysis was as described . Anti-LATS1 polyclonal antibody (pAb, Yu03) was produced previously in our laboratory . Monoclonal antibodies (mAbs) for p53, CDC2, Bcl-2, and Bax were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-b-actin mAb was obtained from Sigma (St. Louis, MO, USA).
Kinase assay
A total of 200 mg protein lysate was precleared with either protein A-agarose or protein G-agarose beads (Boehringer Mannheim, Germany) and subsequently incubated with 2 mg of Y03 anti-LATS1 pAb and anti-cyclin B1 mAb at 48C for 2 h. The antibodies were then precipitated with beads. The precipitated beads were washed three times with lysis buer (50 mM Tis-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% NP40, 0.3 mg/ml antipain-HCl, 50 mg/ml Bestatin, 0.1 mg/ml Chymostatin, 0.3 mg/ml E-64, 50 mg/ml leupeptin, 50 mg/ml papstatin, 0.3 mg/ml phosphoramidon, 2 mg/ml pefabloc, 50 mg/ml aprotinin) and once with kinase buer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 1 mM EGTA), and incubated in 20 ml of reaction buer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 2 mM DTT, 1 mM NaVO 4 , 0.1 mM ATP, 10 mCi [a-32 P]ATP, 5 mg histone H1) at room temperature for 20 min. Five ml of 56Laemmli sample buer was added to stop the reaction. The phosphorylation of histone H1 was examined by separating the samples on a 15% SDS ± PAGE gel and autoradiography.
TUNEL assay
In situ detection of apoptotic cells was performed using In Situ Cell Death Detection Kit (Boehringer Mannheim) following the manufacturer's instruction. In brief, about 1610 5 HCT116 cells were seeded in each well of 6-well plate containing cover slip 24 h prior to infection. The cells were then infected with either Ad or LATS1-Ad for 2 h at 200 MOI. Under this condition, 100% of the cells were infected by virus. After incubation at 378C for 72 h, the cells were ®xed in 4% paraformaldehyde/PBS (pH 7.4) for 1 h at RT, permeabilized with 0.1% Triton X-100, 0.1% sodium citrate for 2 min on ice, and incubated with TUNEL reaction mixture (in a humidi®ed chamber for 60 min at 378C in the dark. After counterstained with propodium iodide (PI), image acquisition was performed using MRC-1024 Laser Scanning Confocal Imaging System (Becton Dickinson). For FACS and caspase-3 activity analysis, cells were infected with adenoviruses at various MOI for 2 h. After 48 h, both the adherent and¯oating cells are collected and processed. The procedures for FACS and caspase-3 activity assay were as described (Yang et al., 2000) .
